Studii clinice pentru BPOC în Georgia
12 studii pentru BPOC caută participanți în Georgia.
Orașe în Georgia
Text oficial al studiului (în engleză)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Appalachian Clinical Research- Site Number : 8400060, Adairsville
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 1 oct. 2026 · NCT07190222To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Centricity Research Columbus, Rincon
În curs de recrutareFaza 2
Vârste de la 40 la 85 · Toate sexele · Actualizat 30 sept. 2026 · NCT07684820A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
În curs de recrutareFaza 4
Vârste de la 40 la 85 · Toate sexele · Actualizat 22 sept. 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
- Primeway Clinical Research- Site Number : 8400121, Fayetteville
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 22 sept. 2026 · NCT07190209A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Atlanta
- Research Site, Cordele
- Research Site, Decatur
- și încă 1
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 3 sept. 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Atlanta
- Research Site, Lithonia
- Research Site, Rincon
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 3 sept. 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Cpcc-Research Llc, East Point
- Centricity Research Rincon Pulmonology, Rincon
În curs de recrutareFaza 2/3
Vârste de la 35 la 80 · Toate sexele · Actualizat 31 aug. 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Savannah
- Research Site, Tucker
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 26 aug. 2026 · NCT06283966eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Cordele
- GSK Investigational Site, Dunwoody
În curs de recrutareFaza 3
Vârste de la 40 la 75 · Toate sexele · Actualizat 28 iul. 2026 · NCT07177339Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
În curs de recrutareFaza 2
Vârste de la 35 la 89 · Toate sexele · Actualizat 15 mai 2026 · NCT05937854Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Adairsville
- GSK Investigational Site, Cordele
- GSK Investigational Site, East Point
- și încă 1
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 9 apr. 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- SpeciCare, Inc, Gainesville
În curs de recrutareStudiu observațional
Vârste de 50 ani și peste · Toate sexele · Actualizat 5 aug. 2025 · NCT06122077Sursă: ClinicalTrials.gov, date preluate la 2 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.